Risk of Post-Acute Sequelae of SARS-CoV-2 Remains High Even with Vaccination During Omicron Era: Study

United States: A recent study published in the New England Journal of Medicine concluded that throughout the pandemic, the cumulative incidence of PASC during the first year after SARS-CoV-2 infection decreased whereas in the omicron era, the risk of post-acute sequelae of SARS-COV-2 infection remained substantial among vaccinated persons who had SARS-CoV-2 infection.

Post-acute sequelae of SARS-CoV-2 infection (PASC), commonly referred to as long COVID. It refers to a range of symptoms that persist for weeks or months after the acute phase of COVID-19 has resolved. Fatigue, tiredness, shortness of breath, cough, headache, joint pain etc are the common symptoms that are associated with SARS-CoV-2 infection. Considering this, Yan Xie, from the Division of Pharmacoepidemiology (Y.X.), Washington University, St.Louis, et.al conducted a study to evaluate the cumulative incidence of PASC during the first year after SARS-CoV-2 infection.

For this purpose, the research team used the records of the Department of Veterans Affairs from March 1, 2020, and January 31, 2022, to build a study population of 441,583 veterans who were infected with SARS-CoV-2 infection and 4,748,504 noninfected participants were used as a control group. After 1 year of SARS-CoV-2 infection, the cumulative incidence of PASC was estimated during the pre–delta, delta, and omicron eras of covid-19.

The study assessed 206,011 persons with no vaccination and SARS-CoV infection during the pre delta era, and 54,002 persons with no vaccination and SARS-CoV-2 infection during the Delta era. 84,943 persons with vaccination and SARS-CoV-2 infection were evaluated during the omicron era.

The findings revealed that:

• Unvaccinated persons infected with SARS-CoV-2, the cumulative incidence of PASC during the first year after infection was 10.42 events per 100 persons, in the pre-delta era, 9.51 events per 100 persons in the delta era, and 7.76 events per 100 persons in the omicron era.

• Among vaccinated persons, the cumulative incidence of PASC at 1 year was 5.34 events per 100 persons during the delta era and 3.50 events per 100 persons during the omicron era. Vaccinated persons had a lower cumulative incidence of PASC at 1 year than unvaccinated persons

• Decomposition analyses showed 5.23 fewer PASC events per 100 persons at 1 year during the omicron era than during the pre-delta and delta eras combined; 28.11% of the decrease was attributable to era-related effects (changes in the virus and other temporal effects), and 71.89%was attributable to vaccines.

“The researchers concluded that in the omricon era, the chances of infection by SARS-CoV-2 remained among vaccinated persons. The incidence of PASC during first year after DARS-CoV-2 infection decreased over the course of a pandemic”, researchers concluded.

Reference

Xie, Y., Choi, T., & Al-Aly, Z. (2024). Postacute Sequelae of SARS-CoV-2 Infection in the Pre-Delta, Delta, and Omicron Eras. The New England journal of medicine, 10.1056/NEJMoa2403211. Advance online publication. https://ift.tt/k37zdpw



from Medical News, Health News Latest, Medical News Today - Medical Dialogues | https://ift.tt/6lUsecX

Comments

Post a Comment

Popular posts from this blog

'Details sought include Third-party info, hence exempted under RTI Act': NMC on RTI query on Faculty Gap in Medical Colleges

Image
New Delhi:  Stating that the details sought under the RTI includes third-party information, the National Medical Commission (NMC) has refused to disclose the names of the medical colleges that fell short on faculty counts and other teaching infrastructure. Recently activist Dr. KV Babu filed an application under the Right to Information Act seeking the details of the notices issued by the NMC Undergraduate Medical Education Board (UGMEB) to the medical colleges for deficiencies in Clinical Material and staff during the period from 01/01/2023 to 30/04/2024. He also sought to know the details of the fine imposed or the action taken by the NMC UG Board from 01/01/2023 to 30/04/2024. In response, the Apex medical regulatory body in India has said that the concerned information includes third party information. "Since the information sought by you, includes third party information, hence the same is exempted for as per Section 8(1) (j) of the Right to Information Act, 2005," th...
Read more

ICMR invites proposals for Centre for Advanced Research under Extramural Research Program, Details

Image
New Delhi- Through a notice, the Indian Council of Medical Research (ICMR) has called for concept proposals for the Centre for Advanced Research (CAR), under the Extramural Research Program. The Last Date for concept proposal is November 21, 2024. Under its Extramural Research Programme, the Indian Council of Medical Research (ICMR) funds the Centre for Advanced Research (CAR) to promote advanced research by experienced research teams.   What the CAR is expected to do: Conducting decisive research that helps in solving an important healthcare problem by a research team. It can have single or multiple linked research projects with clear deliverables. It encourages in-depth research, to generate new knowledge and solutions for health problems in multiple aspects of causation, progression, management and prevention. Priority diseases or conditions: Research teams planning to undertake studies in finding solutions for prevention, screening, diagnosis, treatment or rehabilita...
Read more

Zasocitinib therapy highly efficacious for treatment of severe plaque psoriasis: JAMA

Image
A recent study published in the Journal of American Medical Association revealed that Zasocitinib could be a breakthrough in the treatment of moderate to severe plaque psoriasis. Psoriasis is a chronic inflammatory skin condition characterized by red, scaly patches, affects millions throughout the globe. While several treatments exist, the demand for new, effective, and well-tolerated oral therapies remains high. Zasocitinib, a highly selective allosteric tyrosine kinase 2 (TYK2) inhibitor, emerges as a promising candidate to meet this need. This trial was conducted between August 2021 and September 2022 across 55 centers in the US and Canada and found that Zasocitinib not only significantly improved skin clearance in patients but also expressed a favorable safety and tolerability profile. The study enrolled a total of 287 participants aged between 18 and 70 years, each with a Psoriasis Area and Severity Index (PASI) score of 12 or greater, a Physician’s Global Assessment score of 3...
Read more